Clinical Trials

Accrual Status
Limit to SWOG Trials

1033 Results

Closed
Phase
Accrual
41%
SWOG Clinical Trial Number
SWOG-9158
Closed
Phase
Accrual
70%
Published
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9140
Closed
Phase
Accrual
15%
SWOG Clinical Trial Number
SWOG-9101
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9003
Closed
Phase
SWOG Clinical Trial Number
SWOG-9205

Central Prostate Cancer Serum Repository Protocol

Research Committee(s)
Genitourinary Cancer
Activated
10-01-1992
Closed
10-01-2006
Closed
Phase
Published
SWOG Clinical Trial Number
SWOG-9225

Pharmacokinetics of Isotretinoin or All Trans Retinoic Acid: An Ancillary Study to SWOG-9132

Research Committee(s)
Gynecologic Cancer
Activated
09-15-1992
Closed
06-01-1996
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9132

Evaluation of Alpha Interferon/Isotretinoin or Alpha Interferon/All Trans Retinoic Acid in Cervical Cancer, Phase II

Research Committee(s)
Gynecologic Cancer
Activated
09-15-1992
Closed
05-15-1996
Closed
Phase
Accrual
75%
Published
SWOG Clinical Trial Number
SWOG-9133
Closed
Phase
Accrual
65%
Published
SWOG Clinical Trial Number
SWOG-9104
Closed
Phase
Accrual
86%
Published
SWOG Clinical Trial Number
SWOG-9005
Closed
Phase
Accrual
57%
Published
SWOG Clinical Trial Number
SWOG-9150

Evaluation of Topotecan in Gastric Cancer, Phase II

Research Committee(s)
Gastrointestinal Cancer
Activated
07-15-1992
Closed
10-15-1993
Closed
Phase
Accrual
58%
Published
SWOG Clinical Trial Number
SWOG-8955

Treatment of Stage D, Hormone Refractory Carcinoma of the Prostate with 5/Fluorouracil and Roferon-A®, Phase II

Research Committee(s)
Genitourinary Cancer
Activated
06-15-1992
Closed
11-01-1993
Closed
Phase
Accrual
35%
SWOG Clinical Trial Number
SWOG-9147

Evaluation of Tamoxifen in Desmoid Tumors, Phase II

Activated
06-01-1992
Closed
08-01-1996
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9116
Closed
Phase
Accrual
62%
Published
SWOG Clinical Trial Number
SWOG-9124

Evaluation of Edatrexate (EDX) in Patients with Relapsed or Refractory Germ Cell Tumors, Phase II

Research Committee(s)
Genitourinary Cancer
Activated
06-01-1992
Closed
09-01-1996